Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

International Journal of Pharmacology

Year: 2014  |  Volume: 10  |  Issue: 4  |  Page No.: 231 - 236

Efficacy and Safety of Micafungin as Prophylaxis for Invasive Fungal Disease in Neutropenic Patients with Hematologic Malignancies

Liping Wan, Chun Wang, Lin Liu, Xiaoqiong Tang, Jinghua Wang, Yue Guan, Ming Jiang, Xianlin Duan, Xiaoyan Ke, Hongmei Jing, Jiong Hu, Ling Wang, Yuming Li and Li Geng

Abstract

Invasive Fungal Disease (IFD) is a major cause of death in severe neutropenic patients with hematologic malignancies. Micafungin, a new echinocandin antifungal drug, is effective in treating IFD. However, the efficacy and safety of micafungin in preventing IFD in severe neutropenic patients with hematologic malignancies have not been demonstrated. A prospective and multicenter clinical study was conducted to evaluate the efficacy and safety of micafungin as prophylaxis for IFD. Micafungin 50 mg daily was administered intravenously to 117 high-risk patients with hematologic malignancies undergoing intensive chemotherapy or Hematopoietic Stem Cell Transplantation (HSCT), for a median of 24 days. Successful prophylaxis (no proven, probable or possible IFD up to 1 week after the end of prophylactic treatment) was achieved in 88.54% patients. No patient developed proven IFD during treatment and only 2.08% had probable IFD and 9.38% possible IFD. Micafungin potentially accounted for adverse events in 6.84% of patients. No severe adverse events attributable to micafungin were seen. Micafungin 50 mg daily is a promising prophylactic antifungal therapy for neutropenic patients with hematologic malignancies.

Cited References Fulltext